Ultrasonographic and endocrine evaluation of three regimes for oestrus and ovulation synchronization for sheep in the subtropics.
This study aimed to evaluate three regimes for oestrus and ovulation synchronization in Farafra ewes in the subtropics. During autumn, 43 ewes were assigned to (i) controlled internal drug releasing (CIDR)-eCG group, treated with CIDR for 12 days and eCG at insert withdrawal, n=13; (ii) PGF2alpha-PGF2alpha group, treated with two PGF2alpha injections at 11 days interval, n=14; and (iii) GnRH-PGF2alpha-GnRH group, treated with GnRH, followed 5 days later with PGF2alpha and 24 h later with a second GnRH, n=16. Oestrus-mating detection was carried out at 4 h intervals starting on day 0 [the day of CIDR withdrawal (CIDR-eCG group), the day of second PGF2alpha treatment (PGF2alpha-PGF2alpha group) and the day of PGF2alpha treatment (GnRH-PGF2alpha-GnRH group)]. Ovarian dynamics was monitored by ultrasound every 12 h beginning on day 0 and continued for 4 days. Blood samples were obtained daily for progesterone (P4) and oestradiol 17beta (E2) estimation starting on day 0 and continued for 4 days. The obtained results showed that, oestrus expression, ovulation and conception were greater (p<0.05) in CIDR-eCG and PGF2alpha-PGF2alpha groups than in GnRH-PGF2alpha-GnRH group. All ewes of PGF2alpha-PGF2alpha group presented, on day of second PGF2alpha injection with mature CL (P4>2.0 ng/ml), compared to 42.9% in GnRH-PGF2alpha-GnRH group (p=0.01). The peak of oestrus occurred 32-52, 48-60 and 28-96 h after the end of treatment in CIDR-eCG, PGF2alpha-PGF2alpha and GnRH-PGF2alpha-GnRH groups, respectively. Ovulation started 48 h after treatment in all groups and extended for 24, 36 and 48 h for CIDR-eCG, PGF2alpha-PGF2alpha and GnRH-PGF2alpha-GnRH groups, respectively. Results demonstrated that oestrus and ovulation synchronization could be efficiently achieved in Farafra ewes using either CIDR-eCG or PGF2alpha-PGF2alpha regimes; however, the GnRH-PGF2alpha-GnRH treatment induced a more spread oestrus and ovulation that may make the protocol inadequate for timed artificial insemination.
Ali
A
A
Department of Theriogenology, Faculty of Veterinary Medicine, Assiut University, Assiut 71526, Egypt. ahmedali77@hotmail.com
Hayder
M
M
Saifelnaser
E O H
EO
D000818:Animals; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000494:pharmacology; D002980:Climate; D003692:Delayed-Action Preparations; D015237:Dinoprost / Q000008:administration & dosage / Q000494:pharmacology; D004958:Estradiol / Q000097:blood; D004973:Estrus Synchronization / Q000187:drug effects*; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000494:pharmacology*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology; D007315:Insemination, Artificial / Q000662:veterinary; D008297:Male; D010062:Ovulation Induction / Q000662:veterinary*; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D012756:Sheep / Q000502:physiology*; D014463:Ultrasonography / Q000662:veterinary*
D006063:Chorionic Gonadotropin; D003692:Delayed-Action Preparations; D005300:Fertility Agents, Female; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D015237:Dinoprost